Dr FAGNONI Philippe

Fiche personne

coordonnées

Hôpital Mitterrand
14 rue Gaffarel
21079 DIJON Cedex

03 80 29 34 35

philippe.fagnoni@chu-dijon.fr

Territoire

Bourgogne

Statut

Hospitalo-Universitaire

affiliation

Centre Hospitalier Universitaire de Dijon (CHU Dijon)

Inserm UMR 1231 "Centre de recherche translationnelle en médecine moléculaire (CTM)" (Inserm UMR1231 CTM)

Université de Bourgogne (UB)

équipes/plateformes

Equipe UMR 1231 - Equipe "Épidémiologique et recherche clinique en oncologie digestive (EPICAD)"

Recherche

Expertises :
- Recherche:Epidémiologie
- Clinique:Pharmacie

Projets

Regards croisés sur les représentations sociales et les logiques de choix des patients, médecins et aidants vis-à-vis de la prise en charge des patients en situation de cancer du colon et du poumon métastatique non résécable (EOLE)

2016 - Porteurs du projet : Pr LEJEUNE Catherine, Pr SALES-WUILLEMIN Edith - Partenaires : Pr BINQUET Christine, Dr FAGNONI Philippe, Pr TRUCHOT Didier

Cohorte prospective multicentrique d'aidants informels en Bourgogne et Franche-Comté. Cohorte ICE (Informal Carers of Elderly) (Cohorte ICE)

2013 - Porteurs du projet : Pr BONNETAIN Franck, Pr LEJEUNE Catherine, Pr NERICH Virginie - Partenaires : Pr BONNET Magalie, Pr CORMIER Luc, Dr DABAKUYO-YONLI Sandrine, Pr DION Michèle, Dr FAGNONI Philippe, Dr QUIPOURT Valérie, Mme POZET Astrid, Dr MONNIER Florent, Mme BAILLY Vanessa

Publications

Quality of Life and Needs in Caregivers: Results From the Prospective Multicentric Open-Label Randomized Study of Informal Caregivers of Elderly Patients.

Pozet A, Darnis S, Bonnet M, Meurisse A, Dabakuyo-Yonli TS, Lejeune C, Fagnoni P, Gaimard M, Manckoundia P, Quibel C, Marchand M, Anota A, Nerich V

Int J Public Health. 2023 08 30;68:1605459

[Regional management tool and analysis of hospital prescriptions delivered in community pharmacies A Different approach to support French health institutions].

Le Du N, Arbaut JC, Dupont H, Berthou J, Fagnoni P

Ann Pharm Fr. 2022 Feb 10;:

Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.

Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V

Cancer Immunol. Immunother.. 2020 Jul 16;:

Could venous thromboembolism and major bleeding be indicators of lung cancer mortality? A nationwide database study.

Howlett J, Benzenine E, Cottenet J, Foucher P, Fagnoni P, Quantin C

BMC Cancer. 2020 May 24;20(1):461

Are direct oral anticoagulants an economically attractive alternative to low molecular weight heparins in lung cancer associated venous thromboembolism management?

Howlett J, Benzenine E, Fagnoni P, Quantin C

J. Thromb. Thrombolysis. 2020 Feb 4;:

A systematic review of economic evaluation in pancreatic ductal adenocarcinoma.

Gérard C, Fagnoni P, Vienot A, Borg C, Limat S, Daval F, Calais F, Vardanega J, Jary M, Nerich V

Eur. J. Cancer. 2017 Oct;86:207-216

[Hemorrhage treatment: Evaluation of the proper use of fibrinogen concentrate].

Howlett J, Prudent C, De Maistre E, Fagnoni P, Lazzarotti A

Therapie. 2017 Feb;:

Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trial.

Pozet A, Lejeune C, Bonnet M, Dabakuyo S, Dion M, Fagnoni P, Gaimard M, Imbert G, Nerich V, Foubert A, Chotard M, Bonin M, Anota A, Bonnetain F

Trials. 2016 Nov;17(1):531

Clinical and economic impact of drug eluting beads in transarterial chemoembolization for hepatocellular carcinoma.

Vadot L, Boulin M, Guiu B, Aho LS, Vourc'h M, Musat A, Hillon P, Lepage C, Guignard MH, Fagnoni P

J Clin Pharm Ther. 2015 Feb;40(1):83-90

Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma.

Tavernier J, Fagnoni P, Chabrot P, Guiu B, Vadot L, Aho S, Boyer L, Abergel A, Hillon P, Sautou V, Boulin M

Anticancer Res. 2014 Dec;34(12):7247-53.

Generic vancomycin products: Analysis of serum concentrations in patients with acute myeloid leukemia.

Monnier A, Malbranche C, Fagnoni P, Serge Aho L, Guerard P, Sgro C, Guignard MH, Croisier-Bertin D, Chavanet P, Chrétien ML, Caillot D, Boulin M

Ann Pharm Fr. 2014 May;72(3):178-83

Predictive factors of transarterial chemoembolisation toxicity in unresectable hepatocellular carcinoma.

Boulin M, Adam H, Guiu B, Aho LS, Cercueil JP, Di Martino C, Fagnoni P, Minello A, Jouve JL, Hillon P, Bedenne L, Lepage C

Dig Liver Dis. 2014 Apr;46(4):358-62

[Economic impact of strategies using ephedrine prefilled syringes].

Cregut-Corbaton J, Malbranche C, Guignard MH, Fagnoni P

Ann Fr Anesth Reanim. 2013 Nov;32(11):760-5

Result and Cost of hepatic Chemoembolization with loaded Beads in 21 Patients.

Vadot L, Boulin M, Malbranche C, Guiu B, Aho S, Musat A, Pernot C, Guignard MH, Hillon P, Fagnoni P

J Radiol Diagn Interv. 2013 Jan;94(1):52-9.

Incidence and risk factors of anemia in patients with early breast cancer treated by adjuvant chemotherapy.

Chaumard N, Limat S, Villanueva C, Nerich V, Fagnoni P, Bazan F, Chaigneau L, Dobi E, Cals L, Pivot X

Breast. 2012 Aug;21(4):464-7

Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma.

Boulin M, Guiu S, Chauffert B, Aho S, Cercueil JP, Ghiringhelli F, Krause D, Fagnoni P, Hillon P, Bedenne L, Guiu B

Anticancer Drugs. 2011 Sep;22(8):741-8.

[Economic impact of transarterial chemoembolization with drug eluting beads in the treatment of hepatocellular carcinoma].

Malbranche C, Boulin M, Guiu B, Pernot C, Cercueil JP, Serge Aho L, Musat A, Bedenne L, Hillon P, Guignard MH, Fagnoni P

Bull Cancer. 2011 Jun;98(6):671-8

Cost Effectiveness of High-Dose Chemotherapy with Autologous Stem Cell Support as Initial Treatment of Aggressive Non-Hodgkin's Lymphoma

Fagnoni P, Milpied N, Limat S, Deconinck E, Nerich V, Foussard C, Colombat P, Harousseau JL, Woronoff-Lemsi MC

Pharmacoeconomics. 2009;27(1):55-68